We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals

147 hedge funds and large institutions have $207M invested in Vanda Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 54 increasing their positions, 44 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more call options, than puts

Call options by funds: $261K | Put options by funds: $212K

23% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 44

1.43% less ownership

Funds ownership: 75.51% → 74.08% (-1.4%)

4% less funds holding

Funds holding: 153 → 147 (-6)

15% less capital inflows, than outflows

Capital inflows: $20.1M | Capital outflows: $23.7M

16% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 25

Holders
147
Holders Change
-6
Holders Change %
-3.92%
% of All Funds
1.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
54
Reduced
44
Closed
25
Calls
$261K
Puts
$212K
Net Calls
+$49K
Net Calls Change
-$1.26M

VNDA Hedge Fund Activity: Q4 2024 in Review

147 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2024, worth a combined $207M — up 0.24% from $206M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of VNDA and 21 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 54 added.

The largest buyer was Morgan Stanley, adding an estimated $3.48M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $7.47M sold.

  • 147 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2024, down from 153 in Q3 2024.
  • Funds reported $207M of Vanda Pharmaceuticals stock for Q4 2024, up 0.24% quarter-over-quarter.
  • 21 funds opened new Vanda Pharmaceuticals positions in Q4 2024 and 25 closed out, a net change of -4 holders.
  • The largest Vanda Pharmaceuticals buyer in Q4 2024 was Morgan Stanley, an estimated $3.48M added.
  • The largest Vanda Pharmaceuticals seller in Q4 2024 was Nantahala Capital Management, an estimated $7.47M sold.

Based on aggregated 13F filings for Q4 2024.